Xvivo Perfusion AB (publ) (XVIVO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much. Good morning and good afternoon, everyone, and welcome to Exvivo's earnings call for the second quarter of 2026. To get started, we go to slide two, and today's presenters are me, Christoffer Rosenblad, CEO, calling in from Gothenburg, Sweden, and Christoffer Nordstrom, CFO, calling in from Denver in Colorado. And with that, we can go over to slide three, which is the Q2 financials at the glance. The Q2 shows the sales amount in line with the previous quarter, Q1, and with a 36% organic top line growth compared to the same quarter last year. EBITDA was kept at the healthy level, resulting in a good operating cash flow. For the third consecutive quarter, the total cash flow was neutral and hence the cash position stable. Christoffer Nordstrom, our CFO, will get into the details on sales, gross margin, cash flow and EBITDA later in this presentation. If we look into the segments, both the thoracic and abdominal segments are growing rapidly in both regions, North America and Europe. The lung market trend from Q4 last year continued to 2026 with a good lung market growth. I'm also very pleased with the strong kidney cells in the quarter fueled by larger sales footprint in Europe and a growing sales force and most importantly growing interest from clinicians in the United States. We will come back later in the presentation on the progress for the service segment, the actions taken and how we will execute to become the preferred partner in the transplant process. And with that we can go over to the next slide, which is slide number four, which is the same picture but for the first six months of the year. and it shows a similar picture as the quarter. Good stable overall growth comes from strong thoracic growth and healthy abdominal growth. During this ye...